Table 2.
Case reports of HCC treatment with SA monotherapy
|
Publication |
Type of study |
Number of enrolled patients and controls |
Type of Cancer |
SA used for treatment |
Response to treatment-outcome |
|
|---|---|---|---|---|---|---|
| Patients | Controls | |||||
| Raderer 1999
[207] |
Case report |
1 |
- |
Advanced HCC |
LAN SR (30 mg/10d) |
↓AFP, ↑TN, SD |
| Siveke 2003
[208] |
Case report |
1 |
- |
Advanced HCC |
OCT LAR (10 mg/28d) |
CR, ↓AFP |
| Deming 2005
[209] |
Case report |
1 |
- |
Metastatic HCC |
OCT LAR (30 mg) |
↑QoL, ↓AFP, PR |
| Borbath 2012 [210] | Case report | 1 | - | Metastatic HCC with lung and mediastinal nodes, HBV+, | LAN SR (30 mg/14d) | PR |
CR, Complete response.
PR, Partial response.
QoL, Quality of life.
SD, Stable disease.
TN, Tumor necrosis.
AFP, Alpha fetoprotein.